Mcro.Ca
MCRO.CA is a pharmaceutical company that develops and commercializes medical devices and technologies, primarily focused on the aesthetics and dermatology markets.
Business. MCRO.CA is a pharmaceutical company that develops and commercializes medical devices and technologies, primarily focused on the aesthetics and dermatology markets.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MCRO.CA is a pharmaceutical company that develops and commercializes medical devices and technologies, primarily focused on the aesthetics and dermatology markets.
The company's capital structure is characterized by a debt-to-equity ratio of 1.72, indicating a relatively high level of leverage. Its liquidity position is assessed as medium, with a current ratio of 1.35, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess. The company's free cash flow of $90.85 million supports its operational flexibility, although its long-term debt of $333.43 million represents a significant portion of its liabilities.
In terms of profitability, the company's return on equity of 59.76% and return on assets of 14.88% are strong indicators of efficient use of equity and assets to generate profit. These figures suggest the company is performing well relative to its capital base, although a direct comparison to industry medians is necessary to fully assess its competitive position.
The company's revenue is primarily concentrated in the aesthetics and dermatology markets, with a significant portion derived from its core product lines in these segments. There is no detailed geographic breakdown provided, but the company's operations are likely centered in North America, given its listing and market presence.
The company's growth trajectory is supported by its strong operating cash flow of $160.99 million and free cash flow of $90.85 million. While specific revenue growth rates are not provided, the company's capital expenditure of -$42.48 million indicates a focus on cost management and operational efficiency. The outlook for the current fiscal year is positive, with the company expected to maintain its profitability and liquidity.
The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could impact its ability to fund operations without external financing. The company has not indicated any immediate plans for share dilution, and its diluted shares outstanding are the same as its basic shares, suggesting no near-term dilution pressure.
Recent events and filings have not been detailed in the provided data, but the company's financial health and operational performance suggest a stable and well-managed business. The company's strong cash flow and profitability metrics indicate a solid foundation for future growth and resilience against market fluctuations.
- The company has a strong return on equity and return on assets, indicating efficient use of capital.
- The company's liquidity position is moderate, with a current ratio of 1.35.
- The company's debt-to-equity ratio is 1.72, suggesting a relatively high level of leverage.
- The company's free cash flow of $90.85 million supports its operational flexibility.
- The company's risk profile is marked by a medium liquidity risk and a low dilution risk.
- The company's growth trajectory is supported by strong operating and free cash flows.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- MCRO.CA Market data — financials · 2026-05-28